Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Oncology Année : 2007

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

Caroline Bascoul-Mollevi

Résumé

PURPOSE: In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response. PATIENTS AND METHODS: Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule. RESULTS: We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100% specificity) and 11 of 12 nonresponders (92% sensitivity) were classified correctly, for an overall accuracy of 95%. CONCLUSION: After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting.

Domaines

Cancer
Fichier principal
Vignette du fichier
Gene_expression_signature_JCO_Figure1.pdf (27.88 Ko) Télécharger le fichier
Gene_expression_signature_JCO_Del_Rio.pdf (200.28 Ko) Télécharger le fichier
Gene_expression_signature_JCO_Figure2.pdf (11.94 Ko) Télécharger le fichier

Dates et versions

inserm-00147002 , version 1 (15-05-2007)

Identifiants

Citer

Maguy Md del Rio, Franck Molina, Caroline Bascoul-Mollevi, Virginie Copois, Frédéric Bibeau, et al.. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.. Journal of Clinical Oncology, 2007, 25 (7), pp.773-80. ⟨10.1200/JCO.2006.07.4187⟩. ⟨inserm-00147002⟩
206 Consultations
867 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More